Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

The Prevalence of Metabolic Syndrome in Patients With Psoriasis and Psoriatic Arthritis and Its Correlation With Disease Severity and Serum Omentin-1 and Visfatin Levels

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03932110

Enrollment

180

Registered

2019-04-30

Start date

2019-04-15

Completion date

2019-06-14

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Psoriasis Vulgaris, Psoriatic Arthritis

Keywords

psoriasis vulgaris, psoriatic arthritis, metabolic syndrome, omentin, visfatin

Brief summary

In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

Interventions

DIAGNOSTIC_TESTomentin, visfatin

diagnostic blood test

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic 2. Patients older than 18 years 3. Patients who accept dermatological and rheumatic examination 4. Patients not receiving systemic treatment related to the disease in the last 1 month

Exclusion criteria

1. Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis 2. Patients under 18 years 3. Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Design outcomes

Primary

Measure	Time frame	Description
omentin	6 months	Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels
visfatin	6 months	Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026